News & Updates

Treatment with the nonpurine xanthine oxidase inhibitor tigulixostat leads to a significant reduction in serum uric acid (sUA) levels while having an acceptable safety profile, as shown in data from the multicentre, double-blind, parallel-group, dose-finding phase II CLUE trial.

New drug applications approved by US FDA as of 16-31 January 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Some patients with treatment-refractory juvenile dermatomyositis (JDM) appear to respond to abatacept, as shown in a small study.

Treatment with aspirin, warfarin, and nonvitamin K oral anticoagulant (NOAC) results in a reduced risk of thromboembolic events, suggests a recent study.

Progression-free (PFS) and overall survival (OS) are similar between age groups (≥70 and <70 years) among  patients treated with cyclin-dependent kinase (CDK) 4/6 inhibitors from 2015 to 2019, with no significant differences in neutropaenia or thrombocytopaenia toxicity, reports a study.

Treatment with torsemide in survivors of heart failure hospitalization appears to have a similar effect on all-cause mortality over 12 months as furosemide, according to data from the open-label TRANSFORM-HF study.